GlassScriptPhysician profile
Tara Roa
NPI 1043286933
$1,932.89
in general payments reported to CMS, 2019-2025
28 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $349 · 2022: $417 · 2023: $286 · 2024: $574 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,167.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $202.61 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $164.48 | 2021-2025 | Evenity, Prolia, Otezla |
| Dexcom, INC. | $155.68 | 2022-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Novo Nordisk INC | $146.20 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.38 | 2021-2025 | Jardiance, Tradjenta |
| Pfizer INC. | $132.66 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $100.55 | 2021-2022 | |
| Mylan Specialty L.P. | $97.83 | 2021-2024 | Yupelri |
| Abbvie INC. | $82.27 | 2023-2025 | |
| Vivus LLC | $78.61 | 2024 | Qsymia |
| Medtronic, INC. | $74.88 | 2021-2024 | Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $74.42 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $70.50 | 2024-2025 | |
| Cequr Corporation | $50.54 | 2024-2025 | Cequr Simplicity |
| Insulet Corporation | $47.92 | 2024-2025 | Omnipod |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $47.36 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $37.91 | 2022 | |
| Sumitomo Pharma America, INC. | $34.00 | 2023-2025 | Gemtesa |
| Alnylam Pharmaceuticals INC. | $32.28 | 2025 | Givlaari |
| Janssen Pharmaceuticals, INC | $26.18 | 2021 | |
| Xeris Pharmaceuticals, INC. | $24.50 | 2021 | |
| Abbott Laboratories | $19.62 | 2021 | |
| Merck Sharp & Dohme LLC | $19.11 | 2023 | Belsomra |
| Mallinckrodt Hospital Products INC. | $16.13 | 2022 | |
| Daiichi Sankyo INC. | $14.93 | 2022 | |
| Astellas Pharma US INC | $14.75 | 2022 | |
| Neurelis, INC. | $13.80 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.79 | 2023 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Roa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.